CD4 and neoplasm: JNJ77 treatment non-significantly reduced tumour weight and spleen weight, while it significantly decreased the percentage of tumour-infiltrating CD4+ T lymphocytes and further reduced the percentage of Tregs in TDLN (Fig. 4a, b, d, h).